Citius Pharmaceuticals (CTXR) Stock News, Feb-Jul 2025

Citius Pharmaceuticals (NASDAQ:CTXR) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive trading days from June 20, 2025 to July 3, 2025, meeting Nasdaq Listing Rule 5550(a)(2).

As a result, the previously scheduled Nasdaq Hearing Panel has been cancelled, and CTXR will continue to be listed and traded on the Nasdaq Stock Market. CEO Leonard Mazur emphasized the company's commitment to developing critical care products and creating shareholder value.

Citius Oncology (NASDAQ: CTOR) is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), scheduled for the second half of 2025. The company has completed key launch preparations including commercial-scale manufacturing with 60-month shelf life inventory sufficient for 12-18 months post-launch. Distribution agreements with global logistics partners are being finalized to ensure broad U.S. access. The company has garnered significant interest from the medical community, with 70 institutional oncology centers already registered. LYMPHIR has secured NCCN guideline inclusion and a permanent J-code, positioning it well for reimbursement. The recent capital raise by parent company Citius Pharma (NASDAQ: CTXR) supports the launch, while strategic partnership discussions are ongoing to expand market reach.

Citius Pharmaceuticals (NASDAQ: CTXR) has closed its registered direct offering priced at-the-market, raising $6 million through the sale of 4,920,000 shares of common stock (or pre-funded warrants) at $1.22 per share. The offering includes short-term warrants to purchase up to 9,840,000 additional shares at $1.00 per share, potentially generating an additional $9.8 million if fully exercised within 24 months. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the proceeds to support the commercial launch of LYMPHIR™ and for general corporate purposes. The offering was made under a shelf registration statement filed with the SEC.

Citius Pharmaceuticals (NASDAQ: CTXR) has announced a registered direct offering priced at-the-market, aiming to raise up to $15.8 million in total. The initial offering consists of 4,920,000 shares of common stock (or pre-funded warrants) at $1.22 per share, expected to generate $6 million in gross proceeds. Additionally, the company is offering short-term warrants to purchase up to 9,840,000 shares at $1.00 per share, potentially generating another $9.8 million if fully exercised. The warrants will be exercisable immediately and expire after 24 months. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will primarily support the commercial launch of LYMPHIR™ and general corporate purposes. The offering is expected to close around June 11, 2025.

Citius Oncology (CTOR), a subsidiary of Citius Pharmaceuticals (CTXR), has secured a distribution services agreement with Cardinal Health (CAH) for LYMPHIR, their FDA-approved immunotherapy treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults. The partnership positions Cardinal Health as an authorized distributor of record, leveraging their established pharmaceutical distribution network to facilitate LYMPHIR's upcoming U.S. commercial launch. This strategic agreement aims to ensure efficient and reliable delivery of LYMPHIR to healthcare providers and patients, marking a significant milestone in Citius Oncology's launch preparation strategy.

Citius Pharmaceuticals (NASDAQ: CTXR) reported its fiscal Q2 2025 financial results. The company reported a net loss of $11.5 million ($1.27 per share) compared to $8.5 million in Q2 2024. Key financial metrics include R&D expenses of $3.8 million and G&A expenses of $4.8 million. As of March 31, 2025, Citius had only $26,410 in cash and will need additional capital beyond May 2025. The company is focusing on the launch of LYMPHIR through Citius Oncology and has retained Jefferies LLC to evaluate strategic alternatives. Citius is also preparing an FDA submission for its Mino-Lok program following the successful completion of Phase 3 trials. The company recently raised $6 million through equity issuance and completed a $1.735 million registered direct offering in April 2025.

Citius Pharmaceuticals (CTXR) and its oncology subsidiary Citius Oncology (CTOR) announced their participation in the upcoming Jefferies Global Healthcare Conference in New York City from June 3-5, 2025. Chairman and CEO Leonard Mazur will deliver a presentation on Thursday, June 5, 2025, at 3:10 pm ET.

The presentation will be available via live webcast and archived for later viewing on the company's website. Additionally, Mr. Mazur will engage in one-on-one meetings with institutional investors during the conference. Interested investors can arrange meetings through their Jefferies representatives.

Citius Pharmaceuticals (NASDAQ: CTXR) has announced a $2 million registered direct offering of common stock. The company will issue 1,739,131 shares at a purchase price of $1.15 per share, with the option for pre-funded warrants. The offering, expected to close around April 2, 2025, is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent.

The net proceeds, after deducting placement agent fees and offering expenses, will be used to support the commercial launch of LYMPHIR™ and general corporate purposes. The offering is being made through a shelf registration statement filed with the SEC on February 23, 2024, and declared effective on March 1, 2024.

Citius Pharmaceuticals (CTXR) reported its fiscal Q1 2025 results, highlighting preparations for the LYMPHIR commercial launch in H1 2025. The company secured a new J-code (J9161) for LYMPHIR, effective April 1, 2025, and reported promising preliminary results from an ongoing Phase I trial combining LYMPHIR with pembrolizumab.

Financial results showed cash and cash equivalents of $1.1 million as of December 31, 2024. The company reported a net loss of $10.3 million ($1.30 per share), compared to $9.2 million ($1.45 per share) in the prior year. R&D expenses decreased to $2.1 million from $2.6 million, while G&A expenses increased to $5.4 million from $3.7 million.

The company raised $6.5 million through offerings in late 2024 and early 2025, completed a 1-for-25 reverse stock split, and regained Nasdaq compliance.